Erythromycin and Benzoyl Peroxide

Manufacturer
Sandoz Inc. | TOLMAR Inc.
Effective date
2019-10-28
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
9
Source
legacy-cache
Hydrated at
2026-08-02 00:04:48

Label at a glance#

ProductErythromycin and Benzoyl Peroxide
Active ingredientERYTHROMYCIN, BENZOYL PEROXIDE
Label structure11 sections

Indications and uses

Erythromycin and benzoyl peroxide topical gel USP, 3%;5% is indicated for the topical treatment of acne vulgaris.

Dosage and administration

Erythromycin and benzoyl peroxide topical gel USP, 3%;5% should be applied twice daily, morning and evening, or as directed by a physician, to affected areas after the skin is thoroughly washed, rinsed with warm water and gently patted dry.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

 PLEASE READ COMPLETE COMPOUNDING DIRECTIONS
 NOTE: TAP VIAL UNTIL ALL POWDER FLOWS FREELY. ADD ROOM TEMPERATURE  70% ETHYL ALCOHOL TO VIAL (TO THE MARK) AND IMMEDIATELY SHAKE/DISSOLVE COMPLETELY.

For Dermatological Use Only – Not for Ophthalmic Use

Reconstitute Before Dispensing

DESCRIPTION

DESCRIPTION SECTION

Erythromycin and benzoyl peroxide topical gel USP, 3%;5% contains erythromycin [(3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)-oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-ß-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione].

Erythromycin is a macrolide antibiotic produced from a strain of Saccharopolyspora erythraea (formerly Streptomyces erythreus). It is a base and readily forms salts with acids.

Chemically, erythromycin is (C37H67NO13). It has the following structural formula:

318764a6-figure-01
318764a6-figure-01

Erythromycin has the molecular weight of 733.94. It is a white crystalline powder and has a solubility of approximately 1 mg/mL in water and is soluble in alcohol at 25°C.

Erythromycin and benzoyl peroxide topical gel USP, 3%;5% also contains benzoyl peroxide for topical use. Benzoyl peroxide is an antibacterial and keratolytic agent.

Chemically, benzoyl peroxide is (C14H10O4). It has the following structural formula:

318764a6-figure-02
318764a6-figure-02

Benzoyl peroxide has the molecular weight of 242.23. It is a white granular powder and is sparingly soluble in water and alcohol and soluble in acetone, chloroform and ether.

Each gram of erythromycin and benzoyl peroxide topical gel USP, 3%;5% contains, as dispensed, 30 mg (3%) of erythromycin, USP and 50 mg (5%) of benzoyl peroxide, USP in a gel of purified water, USP, alcohol 20%, carbomer homopolymer type C, NF, sodium hydroxide, NF, docusate sodium and fragrance.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug.

Benzoyl peroxide has a keratolytic and desquamative effect which may also contribute to its efficacy. Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid.

MICROBIOLOGY: Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding to 50 S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer–RNA and inhibiting polypeptide synthesis. Antagonism has been demonstrated in vitro between erythromycin, lincomycin, chloramphenicol and clindamycin.

Benzoyl peroxide is an antibacterial agent which has been shown to be effective against Propionibacterium acnes, an anaerobe found in sebaceous follicles and comedones. The antibacterial action of benzoyl peroxide is believed to be due to the release of active oxygen.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Erythromycin and benzoyl peroxide topical gel USP, 3%;5% is indicated for the topical treatment of acne vulgaris.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Erythromycin and benzoyl peroxide topical gel USP, 3%;5% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis.”

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C. difficile colitis.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

For topical use only; not for ophthalmic use. Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating or abrasive agents. If severe irritation develops, discontinue use and institute appropriate therapy.

The use of antibiotic agents may be associated with the overgrowth of nonsusceptible organisms including fungi. If this occurs, discontinue use and take appropriate measures.

Avoid contact with eyes and all mucous membranes.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Patients using erythromycin and benzoyl peroxide topical gel USP, 3%;5% should receive the following information and instructions.

  1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes, nose, mouth, and all mucous membranes.
  2. This medication should not be used for any disorder other than that for which it was prescribed.
  3. Patients should not use any other topical acne preparation unless otherwise directed by physician.
  4. Patients should report to their physician any signs of local adverse reactions.
  5. Erythromycin and benzoyl peroxide topical gel USP, 3%;5% may bleach hair or colored fabric.
  6. Keep product refrigerated and discard after 3 months.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Data from a study using mice known to be highly susceptible to cancer suggests that benzoyl peroxide acts as a tumor promoter. The clinical significance of this is unknown.

No animal studies have been performed to evaluate the carcinogenic and mutagenic potential or effects on fertility of topical erythromycin. However, long-term (2-year) oral studies in rats with erythromycin ethylsuccinate and erythromycin base did not provide evidence of tumorigenicity. There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Pregnancy CATEGORY C: Animal reproduction studies have not been conducted with erythromycin and benzoyl peroxide topical gel USP, 3%;5% or benzoyl peroxide.

There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% diet) prior to and during mating, during gestation and through weaning of two successive litters.

There are no well-controlled trials in pregnant women with erythromycin and benzoyl peroxide topical gel USP, 3%;5%. It also is not known whether erythromycin and benzoyl peroxide topical gel USP, 3%;5% can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Erythromycin and benzoyl peroxide topical gel USP, 3%;5% should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether erythromycin and benzoyl peroxide topical gel USP, 3%;5% is excreted in human milk after topical application. However, erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Therefore, caution should be exercised when erythromycin is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness of this product in pediatric patients below the age of 12 have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

In controlled clinical trials, the incidence of adverse reactions associated with the use of erythromycin and benzoyl peroxide topical gel USP, 3%;5% was approximately 3%. These were dryness and urticarial reaction.

The following additional local adverse reactions have been reported occasionally: irritation of the skin including peeling, itching, burning sensation, erythema, inflammation of the face, eyes and nose, and irritation of the eyes. Skin discoloration, oiliness and tenderness of the skin have also been reported.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Erythromycin and benzoyl peroxide topical gel USP, 3%;5% should be applied twice daily, morning and evening, or as directed by a physician, to affected areas after the skin is thoroughly washed, rinsed with warm water and gently patted dry.

HOW SUPPLIED[/S]

HOW SUPPLIED SECTION

 Compounding Directions[/TC]
 Size(Net Weight) NDC 0781- Benzoyl
Peroxide
Gel
 Active
Erythromycin
Powder
(In Plastic Vial)
 70% Ethyl
Alcohol To Be Added
 23.3 grams(as dispensed) 7054-49 20 grams 0.8 grams 3 mL
     
 46.6 grams(as dispensed) 7094-59 40 grams 1.6 grams 6 mL

TO THE PHARMACIST: IMPORTANT – Prior to dispensing, tap vial until all powder flows freely. Add indicated amount of room temperature 70% ethyl alcohol to vial (to the mark) and immediately shake to completely dissolve erythromycin. Add this solution to gel and stir with supplied spatula until homogeneous in appearance (1 to 1 ½ minutes). Erythromycin and benzoyl peroxide topical gel USP, 3%;5% should then be stored under refrigeration. Do not freeze. Place a 3-month expiration date on the label.

NOTE: Prior to reconstitution, store at 20° to 25°C (68° – 77°F). [See USP Controlled Room Temperature].

After reconstitution, store under refrigeration between 2° and 8°C (36° – 46°F).

Do not freeze. Keep tightly closed. Keep out of the reach of children.

Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.

Manufactured by
TOLMAR Inc.
Fort Collins, CO 80526 for
Sandoz Inc.
Princeton, NJ  08540

04275 Rev. 6 04/11

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

 0.8g vial0.8g vial 1.6g vial1.6g vial 23.3g jar23.3g jar 

46.6g jar
46.6g jar

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0781-7054-49GM - Gram0781-705489999d63-c1cd-43de-b3b0-5a11418142ab12012-07-24
0781-7054-59GM - Gram0781-70549a93cfbc-d48b-412d-b2a7-3adc0401e18212013-02-11
0781-7094-59GM - Gram0781-7094678c9fdb-1914-426c-9642-8e8f0f63796212012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
BENZOYL PEROXIDEACTIVE INGREDIENTW9WZN9A0GM7
ERYTHROMYCINACTIVE INGREDIENT63937KV33D7
BENZOYL PEROXIDEACTIVE MOIETYW9WZN9A0GM7
ERYTHROMYCINACTIVE MOIETY63937KV33D7
ALCOHOLINACTIVE INGREDIENT3K9958V90M7
CARBOMER HOMOPOLYMER TYPE CINACTIVE INGREDIENT4Q93RCW27E7
DOCUSATE SODIUMINACTIVE INGREDIENTF05Q2T2JA07
LIMONENE, (+)-INACTIVE INGREDIENTGFD7C86Q1W7
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I7
WATERINACTIVE INGREDIENT059QF0KO0R7

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 16 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 5 · 256 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
ALCOHOLALCOHOL3K9958V90MAEROSOL / NASAL20 mgExact identifier — unii candidate
59 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MPASTE / DENTAL1.8 %w/wExact identifier — unii candidate
59 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVITREALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, COATED / ORAL0.08 mgExact identifier — unii candidate
174 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSUSPENSION / RECTAL0.35 %v/vExact identifier — unii candidate
59 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / TOPICAL2445 mgExact identifier — unii candidate
59 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION, CONCENTRATE / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICREAM / TOPICAL69 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, DELAYED RELEASE / ORAL4 mgExact identifier — unii candidate
174 equally ranked IID candidates
DOCUSATE SODIUMDOCUSATE SODIUMF05Q2T2JA0TABLET, COATED / ORAL1 mgExact identifier — unii candidate
11 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MGEL / DENTAL1.8 %w/wExact identifier — unii candidate
59 equally ranked IID candidates
DOCUSATE SODIUMDOCUSATE SODIUMF05Q2T2JA0SUSPENSION / ORAL48 mgExact identifier — unii candidate
11 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / SUBCUTANEOUS31.45 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRA-ARTERIAL176 mgExact identifier — unii candidate
174 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / NASAL10 mg/1mlExact identifier — unii candidate
59 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MGEL, METERED / TRANSDERMAL3675 mgExact identifier — unii candidate
59 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISYRUP / ORAL71 mg/5mlExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / SOFT TISSUEADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / SOFT TISSUEADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / IRRIGATIONADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR7.01 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILIQUID / ORAL2 mg/5mlExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IDROPS / OPHTHALMICNAExact identifier — unii candidate
174 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MDROPS / ORAL210 mg/1mlExact identifier — unii candidate
59 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IGEL / TRANSDERMAL472 mgExact identifier — unii candidate
174 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MGEL / TRANSDERMAL7360 mgExact identifier — unii candidate
59 equally ranked IID candidates
LIMONENE, (+)-LIMONENE, (+)-GFD7C86Q1WTABLET, ORALLY DISINTEGRATING / ORAL1 mgExact identifier — unii candidate
3 equally ranked IID candidates
DOCUSATE SODIUMDOCUSATE SODIUMF05Q2T2JA0INJECTION / INTRAMUSCULAR0.02 %w/vExact identifier — unii candidate
11 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / PERIODONTALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRAVASCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IFILM / BUCCAL0.09 mgExact identifier — unii candidate
174 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MAEROSOL, SPRAY / RESPIRATORY (INHALATION)35.75 %w/wExact identifier — unii candidate
59 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MLOTION / TOPICAL305 mgExact identifier — unii candidate
59 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRADERMALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
DOCUSATE SODIUMDOCUSATE SODIUMF05Q2T2JA0TABLET / ORAL50 mgExact identifier — unii candidate
11 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / PERINEURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IPOWDER / RESPIRATORY (INHALATION)ADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAVITREALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILIQUID / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / RESPIRATORY (INHALATION)0.08 %w/vExact identifier — unii candidate
59 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IENEMA / RECTAL0.44 %v/vExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IEMULSION / TOPICAL0.2 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION, CONCENTRATE / INTRAVENOUS4000 mgExact identifier — unii candidate
59 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSPRAY / NASAL20 mgExact identifier — unii candidate
59 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRACAUDALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MINJECTION, SOLUTION / INTRAMUSCULAR1000 mgExact identifier — unii candidate
59 equally ranked IID candidates
CARBOMER HOMOPOLYMER TYPE CCARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED)4Q93RCW27EOINTMENT, AUGMENTED / TOPICAL23 mgExact identifier — unii candidate
9 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IOINTMENT / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR27 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRADERMALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRADISCALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISPRAY / NASALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MLIQUID / ORAL3563 mgExact identifier — unii candidate
59 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MCAPSULE / ORAL882 mgExact identifier — unii candidate
59 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDEBENZOYL PEROXIDE; ERYTHROMYCIN5%;3%GEL / TOPICAL2004-03-29

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29d4dbc9d85df4…
2026-10-15 13:18:302026-09A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29c2088c7a36db…
2026-09-14 22:38:342026-08A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-2984e616aacf4f…
2026-08-18 06:07:402026-07A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-2931067a03dcf5…
2025-08-23 18:47 UTC2025-08A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-296a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-2903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-292680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-295bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-2979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-291e350fbaab3a…
2024-05-31 18:47 UTC2024-05A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-298072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-295c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-295d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-294b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICALAB2004-03-2974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICALAB2004-03-2987673890dc5c…
2021-03-12 10:30 UTC2021-03A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICALAB2004-03-295aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICALAB2004-03-298869cabd3fbd…
2020-11-12 02:37 UTC2020-11A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICALAB2004-03-29c0c555d07b60…
2019-12-14 00:12 UTC2019-12A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICALAB2004-03-293f01610625f2…
2019-09-15 20:21 UTC2019-09A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICALAB2004-03-29b00525d2431f…
2019-07-19 19:46 UTC2019-07A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICALAB2004-03-29ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-296a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-291c564ffb4f44…
2023-12-20 04:57 UTC2023-12A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-299b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-293f0d92c62455…
2023-05-13 08:27 UTC2023-05A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-29053a50430f4f…
2023-01-26 05:58 UTC2023-01A065112-001ERYTHROMYCIN AND BENZOYL PEROXIDE5%;3%GEL / TOPICAL2004-03-293bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2019-12-13 00:20 UTC2019-12A065112-001AB174a2ff9319b5…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A065112-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A065112-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A065112-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A065112-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A065112-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A065112-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A065112-001AB1ea99ee380514…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
73446116-1834-415d-9636-0b1dc56eb72ca3061440-9f66-4539-9db3-4f13bd662b702024-02-03Warnings, Adverse reactionsExact identifier
spl set id: a3061440-9f66-4539-9db3-4f13bd662b70

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.